S. Wieland, R. Thimme, R. H. Purcell, and F. Chisari, Genomic analysis of the host response to hepatitis B virus infection, Proc. Natl. Acad. Sci. U.S.A, vol.101, pp.6669-6674, 2004.

C. Dunn, Temporal analysis of early immune responses in patients with acute hepatitis B virus infection, Gastroenterology, vol.137, pp.1289-1300, 2009.

H. B. El-serag, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, vol.142, pp.1264-1273, 2012.

, European Association for the Study of the, L. EASL. Clinical Practice guidelines on the management of hepatitis B virus infection, European Association for the Study of the Liver. Electronic address, vol.67, pp.370-398, 2017.

C. Trepo, H. L. Chan, and A. Lok, Hepatitis B virus infection, Lancet, vol.384, issue.14, pp.60220-60228, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02649042

A. S. Lok, F. Zoulim, G. Dusheiko, and M. G. Ghany, Hepatitis B cure: From discovery to regulatory approval, Hepatology, vol.66, pp.1296-1313, 2017.

F. Zoulim, F. Lebosse, and M. Levrero, Current treatments for chronic hepatitis B virus infections, Curr. Opin. Virol, vol.18, pp.109-116, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01796195

L. Belloni, IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome, J. Clin. Investig, vol.122, pp.529-537, 2012.

J. Lucifora, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, vol.343, p.62, 2014.

Y. Xia, Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA without cytolysis A, Gastroenterology, vol.150, pp.194-205, 2016.

J. H. Bockmann, Comparative analysis of the antiviral effects mediated by type I and III Interferons in Hepatitis B virusinfected Hepatocytes, J. Infect. Dis, vol.220, pp.567-577, 2019.

A. Suslov, T. Boldanova, X. Wang, S. Wieland, and M. H. Heim, Hepatitis B virus does not interfere with innate immune responses in the human liver, Gastroenterology, vol.154, pp.1778-1790, 2018.

Y. Xia, Secreted interferon-inducible factors restrict Hepatitis B and C virus entry in vitro, J. Immunol. Res, 2017.

I. H. Park, K. W. Baek, E. Y. Cho, and B. Y. Ahn, PKR-dependent mechanisms of interferon-alpha for inhibiting hepatitis B virus replication, Mol. Cells, vol.32, pp.167-172, 2011.

R. Yan, The Interferon-inducible protein tetherin Inhibits Hepatitis B virus virion secretion, J. Virol, vol.89, pp.9200-9212, 2015.

N. Isorce, Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus, Antivir. Res, vol.130, pp.36-45, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01797274

Y. Xia and U. Protzer, Control of Hepatitis B virus by cytokines, vol.9, 2017.

M. Hosel, Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection, Hepatology, vol.50, pp.1773-1782, 2009.

Z. Valaydon, The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde, Clin. Transl. Immunol, vol.5, 2016.

R. E. Lanford, GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees, Gastroenterology, vol.144, pp.1508-1517, 2013.

Z. Meng, Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection, Antivir. Res, vol.125, pp.14-24, 2016.

S. Menne, Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B, J. Hepatol, vol.62, pp.1237-1245, 2015.

J. Lucifora, Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes, Sci. Rep, vol.8, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01953649

C. Niu, Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism, J. Hepatol, vol.68, pp.922-931, 2018.

S. Faure-dupuy, Characterization of pattern recognition receptor expression and functionality in liver primary cells and derived cell lines, J. Innate Immun, vol.10, pp.1-10, 2018.

V. Janovec, The MEK1/2-ERK pathway inhibits type I IFN production in plasmacytoid dendritic cells, Front. Immunol, vol.9, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01772995

J. Florentin, HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells, Blood, vol.120, pp.4544-4551, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02507284

M. Bao and Y. J. Liu, Regulation of TLR7/9 signaling in plasmacytoid dendritic cells, Protein Cell, vol.4, pp.40-52, 2013.

M. Swiecki and M. Colonna, The multifaceted biology of plasmacytoid dendritic cells, Nat. Rev. Immunol, vol.15, pp.471-485, 2015.

I. Hirsch, C. Caux, U. Hasan, N. Bendriss-vermare, and D. Olive, Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer, Trends Immunol, vol.31, pp.391-397, 2010.

S. Luangsay, Expression and functionality of toll-and RIG-like receptors in HepaRG cells, J. Hepatol, vol.63, pp.1077-1085, 2015.

L. Aillot, Interaction between toll-like receptor 9-CpG oligodeoxynucleotides and Hepatitis B Virus virions leads to entry inhibition in hepatocytes and reduction of alpha interferon production by plasmacytoid dendritic cells, Antimicrob. Agents Chemother, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01760408

S. R. Mullins, Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies, J. Immunother. Cancer, vol.7, 2019.

N. Surendran, A. Simmons, and M. E. Pichichero, TLR agonist combinations that stimulate Th type I polarizing responses from human neonates, Innate Immun, vol.24, pp.240-251, 2018.

A. B. Macedo, Dual TLR2 and TLR7 agonists as HIV latency-reversing agents, JCI Insight, 2018.

A. Fosdick, Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses, J. Pharmacol. Exp. Ther, vol.348, pp.96-105, 2014.

C. Dental, Hepatitis C virus fails to activate NF-kappaB signaling in plasmacytoid dendritic cells, J. Virol, vol.86, pp.1090-1096, 2011.

A. M. Mitchell, Transmitted/founder hepatitis C viruses induce cell-type-and genotype-specific differences in innate signaling within the liver, MBio, vol.6, 2015.

B. Aouar, Dual role of the tyrosine kinase Syk in regulation of toll-like receptor signaling in plasmacytoid dendritic cells, PLoS ONE, vol.11, p.63, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01357267

L. Chaperot, Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells, J. Immunol, vol.176, pp.248-255, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00286442

M. Jurk, Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848, Nat. Immunol, vol.3, p.499, 2002.

C. A. Leifer and A. E. Medvedev, Molecular mechanisms of regulation of Toll-like receptor signaling, J. Leukoc. Biol, vol.100, pp.927-941, 2016.

Y. J. Liu, IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors, Annu. Rev. Immunol, vol.23, pp.275-306, 2005.

M. De-marcken, K. Dhaliwal, A. C. Danielsen, A. S. Gautron, and M. Dominguez-villar, TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection, Sci. Signal, 2019.

, Scientific RepoRtS |, vol.10, p.12767, 2020.

K. Agarwal, Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment, J. Viral. Hepat, vol.25, pp.1331-1340, 2018.

H. L. Janssen, Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B, J. Hepatol, vol.68, pp.431-440, 2018.

E. Lawitz, Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C, Antivir. Ther, vol.20, pp.699-708, 2015.

J. Scheiermann and D. M. Klinman, Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer, Vaccine, vol.32, pp.6377-6389, 2014.

J. Laino, Targeting of immune cells by dual TLR2/7 ligands suppresses features of allergic Th2 immune responses in mice, J. Immunol. Res, 2017.

B. Lubyova, PRMT5: a novel regulator of hepatitis B virus replication and an arginine methylase of HBV core, PLoS ONE, vol.12, p.82, 2017.

P. David, Metabolic capacities in cultured human hepatocytes obtained by a new isolating procedure from non-wedge small liver biopsies, Hum. Exp. Toxicol, vol.17, p.4, 1998.
URL : https://hal.archives-ouvertes.fr/hal-00502782

F. Gondois-rey, Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1, PLoS ONE, vol.4, p.4319, 2009.